Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
EZ H2 inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
January 2020 |
| gptkbp:category |
gptkb:unknown
Category D |
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
Phase 2
monotherapy or in combination NC T01897571 NC T02601950 NC T03384653 |
| gptkbp:contraindication |
hypersensitivity to tazemetostat
|
| gptkbp:developer |
Epizyme, Inc.
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water soluble in methanol |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tazemetostat
|
| gptkbp:ingredients |
C18 H22 N4 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_used_for |
follicular lymphoma
epithelioid sarcoma |
| gptkbp:lifespan |
approximately 5 hours
|
| gptkbp:manager |
oral
|
| gptkbp:market |
available in the US
available in Europe |
| gptkbp:marketed_as |
the brand name Tazverik
|
| gptkbp:metabolism |
primarily hepatic
|
| gptkbp:population |
adults and children 16 years and older
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
ASCO guidelines
NCCN guidelines |
| gptkbp:requires |
available on FDA website
|
| gptkbp:research |
ongoing studies on efficacy
ongoing studies on safety ongoing studies on combination therapies |
| gptkbp:research_focus |
lymphoma treatment
cancer epigenetics sarcoma treatment EZ H2 mutations |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:scholarships |
available through manufacturer
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea rash thrombocytopenia hyperglycemia hypophosphatemia peripheral edema increased liver enzymes increased creatinine |
| gptkbp:targets |
certain types of cancer
|
| gptkbp:type_of |
1394640-06-0
|
| gptkbp:weight |
358.45 g/mol
|
| gptkbp:bfsParent |
gptkb:Mitsubishi_Tanabe_Pharma
|
| gptkbp:bfsLayer |
4
|